Clinical Characteristics and Cross Analysis of HIV and HCV Co-Infection in Faisalabad Region
AbstractAbout 150 and about 35 million human beings are infected with HCV (hepatitis C virus) as well as HIV (human immunodeficiency virus) respectively. The increasing stress of HIV/HCV coinfection is supposed to infect five to seven million individuals globally due to their coinciding approaches of procurement. Co-infection of HCV/HIV in patients caused them to suffer from more liver-associated mortality and anguish. This paper aims to investigate the spread rate of the HIV and HCV coinfection in District Faisalabad. In this paper, blood samples of patients are evaluated and tested for anti-HIV/HCV antibodies employing the ICT (immune chromatography technique) for HIV/HCV confections. The six out 30 confirmed patients (real-time PCR) for HIV infection who also have HCV infection were analyzed for additional provisional clinical examination. In these patients, the hemoglobin (17.38±0.159 per dL), ALT (77 uL-1) and Hematocrit (50.60±0.255%) levels increased significantly than standard reference values. On the body, these facts could be developed due to HIV/HCV co-infection burden. An inverse relation has been demonstrated by these coinfected patients in the levels of hemoglobin as well as in platelets. With the usages of better supplements/nutrients, the above differential values can be improved and ultimately beneficial for the survival of the infected individuals. The Current paper could be convenient for appropriate perpetuation of HIV/HCV co-infected patients under related treatment.
. R. Seitz, “Human Immunodeficiency Virus (HIV),” Transfus. Med. Hemotherapy, vol. 43, no. 3, pp. 203–222, May 2016, doi: 10.1159/000445852.
. Q. L. Choo, G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton, “Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome,” Science (80-. )., vol. 244, no. 4902, pp. 359–362, 1989, doi: 10.1126/science.2523562.
. G. Shi and T. Suzuki, “Molecular basis of encapsidation of Hepatitis C virus genome,” Frontiers in Microbiology, vol. 9, no. MAR. Frontiers Media S.A., Mar. 07, 2018, doi: 10.3389/fmicb.2018.00396.
. J. J. Lee et al., “Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis,” PLoS One, vol. 9, no. 6, Jun. 2014, doi: 10.1371/journal.pone.0100790.
. D. Lavanchy, “Evolving epidemiology of hepatitis C virus,” Clinical Microbiology and Infection, vol. 17, no. 2. Blackwell Publishing Ltd, pp. 107–115, 2011, doi: 10.1111/j.1469-0691.2010.03432.x.
. G. V Matthews and G. J. Dore, “HIV and hepatitis C coinfection,” Journal of Gastroenterology and Hepatology (Australia), vol. 23, no. 7 PT1. Blackwell Publishing, pp. 1000–1008, Jul. 01, 2008, doi: 10.1111/j.1440-1746.2008.05489.x.
. World Health Organisation (WHO), “WHO | HIV and hepatitis coinfections,” Who, 2015. http://www.who.int/hiv/topics/hepatitis/hepatitisinfo/en/ (accessed Nov. 16, 2020).
. K. Gebo, “HIV and hepatitis C.,” Hopkins HIV Rep., vol. 14, no. 2, pp. 5–6, 2002, Accessed: Nov. 16, 2020. [Online]. Available: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-hepatitis-c.
. Centers for Disease Control and Prevention, “Viral Hepatitis Surveillance, United States,” 2012. https://wwwn.cdc.gov/nndss/conditions/%0Ahttp://www.cdc.gov/hepatitis/Statistics/2012Surveillance/PDFs/2012HepSurveillanceRpt.pdf (accessed Nov. 16, 2020).
. B. R. Yehia et al., “Hepatitis C virus testing in adults living with HIV: A need for improved screening efforts,” PLoS One, vol. 9, no. 7, p. e102766, Jul. 2014, doi: 10.1371/journal.pone.0102766.
. P. R. Spradling et al., “Trends in hepatitis C virus infection among patients in the HIV outpatient study, 1996-2007,” J. Acquir. Immune Defic. Syndr., vol. 53, no. 3, pp. 388–396, Mar. 2010, doi: 10.1097/QAI.0b013e3181b67527.
. G. Liu et al., “HIV prevalence among 338,432 infertile individuals in Hunan, China, 2012-2018: A cross-sectional study,” PLoS One, vol. 15, no. 9 September, Sep. 2020, doi: 10.1371/journal.pone.0238564.
. K. N. Ouma et al., “Evaluation of quantification of hiv-1 RNA viral load in plasma and dried blood spots by use of the semiautomated cobas amplicor assay and the fully automated cobas ampliprep/taqman assay, version 2.0, in Kisumu, Kenya,” J. Clin. Microbiol., vol. 51, no. 4, pp. 1208–1218, Apr. 2013, doi: 10.1128/JCM.03048-12.
. Roche Molecular Diagnostics, “COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0,” 2017. https://diagnostics.roche.com/global/en/products/params/cobas-ampliprep-cobas-taqman-hiv-1-test-v2-0.html (accessed Nov. 17, 2020).
. O. Akkaya, M. Kiyici, Y. Yilmaz, E. Ulukaya, and O. Yerci, “Clinical significance of activity of ALT enzyme in patients with hepatitis C virus,” World J. Gastroenterol., vol. 13, no. 41, pp. 5481–5485, Nov. 2007, doi: 10.3748/wjg.v13.i41.5481.
. V. B. Shah, B. S. Shah, and G. V. Puranik, “Evaluation of non cyanide methods for hemoglobin estimation,” Indian J. Pathol. Microbiol., vol. 54, no. 4, pp. 764–768, Oct. 2011, doi: 10.4103/0377-4929.91494.
. Hanley et. al, “Hemoglobin and its measurement,” Acutecaretesting.Org, 2005. https://acutecaretesting.org/en/articles/hemoglobin-and-its-measurement (accessed Nov. 17, 2020).
. F. Shahidi and Y. Zhong, “Measurement of antioxidant activity,” Journal of Functional Foods, vol. 18. Elsevier Ltd, pp. 757–781, Oct. 01, 2015, doi: 10.1016/j.jff.2015.01.047.
. E. I. Korotkova et al., “Study of total antioxidant activity of human serum blood in the pathology of alcoholism,” Molecules, vol. 18, no. 2, pp. 1811–1818, Feb. 2013, doi: 10.3390/molecules18021811.
. D. Koracevic, G. Koracevic, V. Djordjevic, S. Andrejevic, and V. Cosic, “Method for the measurement of antioxidant activity in human fluids,” J. Clin. Pathol., vol. 54, no. 5, pp. 356–361, 2001, doi: 10.1136/jcp.54.5.356.
. M. G. Valadez-Bustos et al., “A reliable method for spectrophotometric determination of glycine betaine in cell suspension and other systems,” Anal. Biochem., vol. 498, pp. 47–52, 2016, doi: 10.1016/j.ab.2015.12.015.
. R. Ugiagbe and E. Eze, “Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city,” Niger. Med. J., vol. 52, no. 3, p. 167, 2011, doi: 10.4103/0300-1652.86127.
. A. Lodhi et al., “Profile and predictors of hepatitis and HIV infection in patients on hemodialysis of Quetta, Pakistan,” Drug Discov. Ther., vol. 13, no. 5, pp. 274–279, 2019, doi: 10.5582/ddt.2019.01044.
. J. Y. Chen, E. R. Feeney, and R. T. Chung, “HCV and HIV co-infection: Mechanisms and management,” Nature Reviews Gastroenterology and Hepatology, vol. 11, no. 6. Nature Publishing Group, pp. 362–371, 2014, doi: 10.1038/nrgastro.2014.17.
. M. D. Hernandez and K. E. Sherman, “HIV/hepatitis C coinfection natural history and disease progression,” Current Opinion in HIV and AIDS, vol. 6, no. 6. NIH Public Access, pp. 478–482, Nov. 2011, doi: 10.1097/COH.0b013e32834bd365.
Copyright (c) 2021 International Journal of Sciences: Basic and Applied Research (IJSBAR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.